ESMO: Vivace tunes up for phase 3 after midstage mesothelioma trial hits high note – Fierce Biotech

Written by

admin

in

  1. ESMO: Vivace tunes up for phase 3 after midstage mesothelioma trial hits high note  Fierce Biotech
  2. ESMO 2025: VT3989 continues to show promising early results in patients with advanced mesothelioma  MD Anderson Cancer Center
  3. YAP/TEAD inhibitor…

Continue Reading

More posts